Key facts
- This page summarizes Moshe Giladi's Form 4 filing for NovoCure Ltd (NVCR).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 29 Feb 2024, 16:33.
Moshe Giladi - 27 Feb 2024 Form 4 Insider Report for NovoCure Ltd (NVCR)
- Reporting relationship
- Chief Science Officer
- Issuer ticker
- NVCR
- Reported as of
- 27 Feb 2024
- Net transaction value
- +$2,107,557
- SEC form
- 4
- Accepted by SEC
- 29 Feb 2024, 16:33:08 UTC
- Prior SEC filing
- 20 Dec 2023
- Source filing
- View source filing
- Reporting owner signature
- Steven Robbins, as attorney in fact for Giladi, Moshe
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Moshe Giladi filed Form 4 for NovoCure Ltd (NVCR) on 29 Feb 2024.
Change
- Previous filing in this sequence was filed on 20 Dec 2023.
- Current net transaction value: +$2,107,557.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
NVCR
transaction
Ordinary Shares
Award
- Transaction value
- $833,321
- Shares
- +51,124
- Change %
- +274%
- Price
- $16.30
- Shares after
- 69,771
- Date
- 27 Feb 2024
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
NVCR
transaction
Derivative
Stock Options (Right to buy)
Award
- Transaction value
- $1,274,236
- Shares
- +78,174
- Change %
- Price
- $16.30
- Shares after
- 78,174
- Date
- 27 Feb 2024
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 78,174
- Exercise price
- $16.30
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Represents restricted share units that are scheduled to vest in equal installments on February 27, 2025, 2026 and 2027, subject to the reporting person's continued employment through such dates.
Footnote F2
Options to buy 78,174 ordinary shares will vest in equal installments on each of February 27, 2025, 2026, 2027 and 2028, subject to the reporting person's continued employment through such dates.